In summary, this study based on the application of pyrotinib in combination with WBRT exhibited favorable outcomes in patients suffering from HER2+ advanced BC with BM, suggesting the treatment strategy could be an effective method in these patients. The gene discussed is ERBB2; the disease is breast cancer.